Falzon D, Jaramillo E, Schunemann HJ, Arentz M, Bauer M, Bayona J: WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J. 2011, 38: 516-528. 10.1183/09031936.00073611.
Article
CAS
PubMed
Google Scholar
World Health Organization: Toman’s tuberculosis: case detection, treatment, and monitoring. 2004, Geneva: World Health Organization
Google Scholar
Bock N, Reichman LB: Tuberculosis and HIV/AIDS: epidemiological and clinical aspects (world perspective). Semin Respir Crit Care Med. 2004, 25: 337-344. 10.1055/s-2004-829505.
Article
PubMed
Google Scholar
Manosuthi W, Tantanathip P, Prasithisirikul W, Likanonsakul S, Sungkanuparph S: Durability of stavudine, lamivudine and nevirapine among advanced HIV-1 infected patients with/without prior co-administration of rifampicin: a 144-week prospective study. BMC Infect Dis. 2008, 8: 136-10.1186/1471-2334-8-136.
Article
PubMed
PubMed Central
Google Scholar
Rajagopalan S: Tuberculosis and aging: a global health problem. Clin Infect Dis. 2001, 33: 1034-1039. 10.1086/322671.
Article
CAS
PubMed
Google Scholar
Santin CM, Navas EE: Tuberculosis in special populations. Enferm Infecc Microbiol Clin. 2011, 29 (Suppl 1): 20-25.
Article
Google Scholar
Zhan C, Correa-de-Araujo R, Bierman AS, Sangl J, Miller MR, Wickizer SW: Suboptimal prescribing in elderly outpatients: potentially harmful drug-drug and drug-disease combinations. J Am Geriatr Soc. 2005, 53: 262-267. 10.1111/j.1532-5415.2005.53112.x.
Article
PubMed
Google Scholar
Baciewicz AM, Chrisman CR, Finch CK, Self TH: Update on rifampin and rifabutin drug interactions. Am J Med Sci. 2008, 335: 126-136. 10.1097/MAJ.0b013e31814a586a.
Article
PubMed
Google Scholar
Yew WW: Clinically significant interactions with drugs used in the treatment of tuberculosis. Drug Saf. 2002, 25: 111-133. 10.2165/00002018-200225020-00005.
Article
CAS
PubMed
Google Scholar
Martins MA, Carlos PP, Ribeiro DD, Nobre VA, Cesar CC, Rocha MO: Warfarin drug interactions: a comparative evaluation of the lists provided by five information sources. Eur J Clin Pharmacol. 2011, 67: 1301-1308. 10.1007/s00228-011-1086-4.
Article
CAS
PubMed
Google Scholar
Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G: Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012, 141: e44S-e88S. 10.1378/chest.11-2292.
Article
CAS
PubMed
PubMed Central
Google Scholar
Almog S, Martinowitz U, Halkin H, Bank HZ, Farfel Z: Complex interaction of rifampin and warfarin. South Med J. 1988, 81: 1304-1306. 10.1097/00007611-198810000-00024.
Article
CAS
PubMed
Google Scholar
Casner PR: Inability to attain oral anticoagulation: warfarin-rifampin interaction revisited. South Med J. 1996, 89: 1200-1203. 10.1097/00007611-199612000-00014.
Article
CAS
PubMed
Google Scholar
Romankiewicz JA, Ehrman M: Rifampin and warfarin: a drug interaction. Ann Intern Med. 1975, 82: 224-225. 10.7326/0003-4819-82-2-224.
Article
CAS
PubMed
Google Scholar
Self TH, Mann RB: Interaction of rifampin and warfarin. Chest. 1975, 67: 490-491. 10.1378/chest.67.4.490.
Article
CAS
PubMed
Google Scholar
Lee CR, Thrasher KA: Difficulties in anticoagulation management during coadministration of warfarin and rifampin. Pharmacotherapy. 2001, 21: 1240-1246. 10.1592/phco.21.15.1240.33897.
Article
CAS
PubMed
Google Scholar
Krajewski KC: Inability to achieve a therapeutic INR value while on concurrent warfarin and rifampin. J Clin Pharmacol. 2010, 50: 710-713. 10.1177/0091270009353030.
Article
CAS
PubMed
Google Scholar
Kim KY, Epplen K, Foruhari F, Alexandropoulos H: Update on the interaction of rifampin and warfarin. Prog Cardiovasc Nurs. 2007, 22: 97-100. 10.1111/j.0889-7204.2007.05782.x.
Article
PubMed
Google Scholar
Heimark LD, Gibaldi M, Trager WF, O’Reilly RA, Goulart DA: The mechanism of the warfarin-rifampin drug interaction in humans. Clin Pharmacol Ther. 1987, 42: 388-394. 10.1038/clpt.1987.168.
Article
CAS
PubMed
Google Scholar
O’Reilly RA: Interaction of chronic daily warfarin therapy and rifampin. Ann Intern Med. 1975, 83: 506-508. 10.7326/0003-4819-83-4-506.
Article
PubMed
Google Scholar
O’Reilly RA: Interaction of sodium warfarin and rifampin. Studies in man. Ann Intern Med. 1974, 81: 337-340. 10.7326/0003-4819-81-3-337.
Article
PubMed
Google Scholar
Kelly WN, Arellano FM, Barnes J, Bergman U, Edwards IR, Fernandez AM: Guidelines for submitting adverse event reports for publication. Pharmacoepidemiol Drug Saf. 2007, 16: 581-587. 10.1002/pds.1399.
Article
PubMed
Google Scholar
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30: 239-245. 10.1038/clpt.1981.154.
Article
CAS
PubMed
Google Scholar
Horn JR, Hansten PD, Chan LN: Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007, 41: 674-680. 10.1345/aph.1H423.
Article
PubMed
Google Scholar
Ohno Y, Hisaka A, Ueno M, Suzuki H: General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information. Clin Pharmacokinet. 2008, 47: 669-680. 10.2165/00003088-200847100-00004.
Article
CAS
PubMed
Google Scholar
Leveque D, Lemachatti J, Nivoix Y, Coliat P, Santucci R, Ubeaud-Sequier G: Mechanisms of pharmacokinetic drug-drug interactions. Rev Med Interne. 2010, 31: 170-179. 10.1016/j.revmed.2009.07.009.
Article
CAS
PubMed
Google Scholar
Hansten PD, Horn JR: Drug interactions analysis & management. 2010, Saint Louis: Wolters Kluwer
Google Scholar
Rosenthal AR, Self TH, Baker ED, Linden RA: Interaction of isoniazid and warfarin. JAMA. 1977, 238: 2177-10.1001/jama.1977.03280210069029.
Article
CAS
PubMed
Google Scholar
Nishimura Y, Kurata N, Sakurai E, Yasuhara H: Inhibitory effect of antituberculosis drugs on human cytochrome P450-mediated activities. J Pharmacol Sci. 2004, 96: 293-300. 10.1254/jphs.FP0040296.
Article
CAS
PubMed
Google Scholar
Zhou SF, Xue CC, Yu XQ, Li C, Wang G: Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit. 2007, 29: 687-710. 10.1097/FTD.0b013e31815c16f5.
Article
CAS
PubMed
Google Scholar
Otis PT, Feinstein DI, Rapaport SI, Patch MJ: An acquired inhibitor of fibrin stabilization associated with isoniazid therapy: clinical and biochemical observations. Blood. 1974, 44: 771-781.
CAS
PubMed
Google Scholar